Gilead Sciences Inc
NASDAQ:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
NASDAQ:GILD
Watchlist
Price: 90.19 USD 0.48% Market Closed
Market Cap: 112.4B USD
Have any thoughts about
Gilead Sciences Inc?
Write Note

Gilead Sciences Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gilead Sciences Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$113m
CAGR 3-Years
-75%
CAGR 5-Years
-47%
CAGR 10-Years
-36%
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Income from Continuing Operations
-$332.3m
CAGR 3-Years
27%
CAGR 5-Years
17%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
2%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

Gilead Sciences Inc
Glance View

Market Cap
112.4B USD
Industry
Biotechnology

Gilead Sciences Inc. is a biopharmaceutical company that has carved a significant niche in the healthcare industry by focusing on the discovery, development, and commercialization of innovative medicines. Founded in 1987 and based in Foster City, California, Gilead has gained prominence for its groundbreaking antiviral therapies, particularly in the field of HIV and hepatitis C. The company transformed the landscape of these diseases with its flagship products, among them Truvada and Harvoni, which have been instrumental in improving patient outcomes and generating substantial revenues. Gilead continues to build on its legacy by expanding its research into oncology, inflammatory diseases, and cardiovascular conditions, positioning itself as a leader in addressing some of the world's most pressing health challenges. For investors, Gilead Sciences represents a compelling opportunity amid a rapidly evolving pharmaceutical market. The company’s robust pipeline of candidates and ongoing research into novel therapeutic areas suggest potential for sustained growth and profitability. With a strong commitment to innovation, Gilead is not only focused on maximizing the utility of its existing treatments but is also exploring partnerships and acquisitions to bolster its drug development capabilities. As the global demand for effective treatments rises, Gilead stands to benefit from its established reputation, financial resilience, and strategic investments, making it a noteworthy consideration for those looking to invest in a company that is dedicated to improving health outcomes worldwide.

GILD Intrinsic Value
89.71 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Gilead Sciences Inc's Income from Continuing Operations?
Income from Continuing Operations
113m USD

Based on the financial report for Sep 30, 2024, Gilead Sciences Inc's Income from Continuing Operations amounts to 113m USD.

What is Gilead Sciences Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-36%

Over the last year, the Income from Continuing Operations growth was -98%. The average annual Income from Continuing Operations growth rates for Gilead Sciences Inc have been -75% over the past three years , -47% over the past five years , and -36% over the past ten years .

Back to Top